Paper Details

  1. Home
  2. Paper Details

Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

Author: AlbertMatthew L, BachmannAlexander, BiotClaire, BirkhäuserFrédéric D, BisiauxAurélie, BouchierChristiane, BroschRoland, GsponerJoël R, IngersollMolly A, LagranderieMicheline, MarchalGilles, OrgeurMickael, RentschCyrill A, ThalmannGeorge N, WetterauerChristian

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Treatment with BCG Connaught conferred significantly greater 5-yr recurrence-free survival compared with treatment with BCG Tice. BCG Connaught induced stronger T-helper cell 1-biased responses, greater priming of BCG-specific CD8(+) T cells, and more robust T-cell recruitment to the bladder than BCG Tice.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Whether the commonly used bacillus Calmette-Guérin (BCG) strains Connaught and Tice confer different treatment responses in non-muscle-invasive bladder cancer (NMIBC) is unknown. OBJECTIVES: To compare clinical efficacy, immunogenicity, and genetics of BCG Connaught and Tice. DESIGN, S...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2014.02.061

データ提供：米国国立医学図書館（NLM）

BCG Strains in Bladder Cancer: A Race Through the Sands

Bladder cancer, like a persistent sandstorm, is a challenging foe. Immunotherapy using Bacillus Calmette-Guérin (BCG) is a common treatment strategy, but even in the world of medicine, there's no one-size-fits-all approach. This study investigates the intriguing possibility that different BCG strains, which are like different breeds of camels, could impact the treatment's effectiveness.

Connaught vs. Tice: The BCG Strain Showdown

The researchers found that BCG Connaught, one particular strain, proved to be a more effective treatment for non-muscle-invasive bladder cancer (NMIBC), resulting in significantly lower recurrence rates compared to the BCG Tice strain. It's like having two different types of camels for a long desert journey - one might be better suited for the terrain than the other.

The Immune Response: A Vital Oasis

The researchers also discovered that BCG Connaught elicited a stronger immune response, specifically activating a type of immune cell called CD8+ T cells. This suggests that the Connaught strain might be better at mobilizing the body's defenses against the cancer cells. It's like having a strong, well-trained camel caravan to protect you against the dangers of the desert.

Dr. Camel's Conclusion

This research emphasizes that even in the field of immunotherapy, subtle differences can matter. It's a reminder to always strive for a personalized approach to treatment, taking into account individual factors, like the type of BCG strain used in bladder cancer immunotherapy.
Date :
  1. Date Completed 2015-10-19
  2. Date Revised 2021-01-03
Further Info :

Pubmed ID

24674149

DOI: Digital Object Identifier

10.1016/j.eururo.2014.02.061

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.